Clinical Trials
Over the past several years, The John L. Trotter MS Center has participated in multiple clinical trials to evaluate the effectiveness of a variety of drugs and treatments for MS. Currently The John L. Trotter MS Center is the site of several different clinical trials involving patients with all forms of MS, including relapsing remitting, secondary progressive, and primary progressive. We are involved in trials to prevent the future worsening of MS, and to improve the quality of life of our patients.
Funding Sources
- The Barnes-Jewish Hospital MS Fund - contributions from patients, community members, foundations and corporations
- The National Multiple Sclerosis Society
- The National Institutes of Health
Links
National Multiple Sclerosis Society
National Multiple Sclerosis Society Gateway
Washington University School of Medicine
Clinical Trials Currently Enrolling Patients
Several clinical trials of treatments for MS patients are now recruiting MS patients. The trials we do change frequently, so it is best to inquire if you have questions. The following studies are still enrolling patients:
1.) ESTRIOL STUDY: For female patients with relapsing MS who are currently taking, or about to begin taking, Copaxone therapy. Patients will be randomized to receive either Estriol, a female hormone thought to be protective in MS, or placebo. Patients will remain on their Copaxone during the study.
2) NERISPIRDINE STUDY: For patients with any type of MS and gait disorder. Patients must be able to walk, but may use assistance. This is a 14 week, placebo-controlled trial of a new drug that may improve walking ability.
WHO IS THE PRINCIPAL INVESTIGATOR (DOCTOR)?
Dorothy Anne H. Cross, MD
660 South Euclid Avenue
Campus Box 8111
Saint Louis, MO 63110
WHERE WILL THE STUDY TAKE PLACE
Washington University School of Medicine
CONTACT:
Samantha Lancia, Clinical Research Assistant. Phone: 314-747-5576
All patients will continue to be patients of their regular physician during and after these clinical trials.
For all of the trials, patients will be able to acquire study medication at no cost and often they will be offered enrollment in an open label phase at the end of the trial.
Participation in the trials is free. Patients will be asked to sign an Informed Consent document.
For further information or if you have questions regarding the suitability of an individual patient for any of these trials, please call our research assistant, Samantha Lancia 314-747-5576.
|
